Summary
Gilead Sciences, Inc. (GILD) reported a strong financial performance for the fiscal year ending December 31, 2015, with total revenues reaching $32.6 billion, a significant increase of 31% year-over-year. This growth was primarily driven by its antiviral products, particularly the Hepatitis C treatments Harvoni and Sovaldi, which accounted for a substantial portion of the revenue. The company also saw continued strength in its HIV franchise, supported by newer single-tablet regimens like Genvoya. While the company demonstrated robust revenue growth and profitability, it also highlighted ongoing investments in research and development, with R&D expenses increasing to $3.0 billion. Gilead's balance sheet remained strong, with cash, cash equivalents, and marketable securities totaling $26.2 billion. The company also returned significant capital to shareholders through share repurchases and initiated a quarterly dividend. Gilead faces a competitive market and ongoing pricing pressures, especially in the HCV segment, and is actively managing legal and patent challenges. The company provided an outlook for 2016, anticipating continued focus on pipeline progression and commercial uptake of its key products.
Financial Highlights
56 data points| Revenue | $32.64B |
| Cost of Revenue | $4.01B |
| Gross Profit | $28.63B |
| R&D Expenses | $3.01B |
| SG&A Expenses | $3.43B |
| Operating Expenses | $10.45B |
| Operating Income | $22.19B |
| Interest Expense | $688.00M |
| Net Income | $18.11B |
| EPS (Basic) | $12.37 |
| EPS (Diluted) | $11.91 |
| Shares Outstanding (Basic) | 1.46B |
| Shares Outstanding (Diluted) | 1.52B |
Key Highlights
- 1Total revenues increased by 31% to $32.6 billion in 2015, driven by strong antiviral product sales.
- 2Antiviral products, including HCV and HIV treatments, generated $30.2 billion in sales, representing 93% of total revenues.
- 3Harvoni and Sovaldi sales were substantial, although Sovaldi sales declined due to patient uptake of Harvoni.
- 4HIV product sales grew, boosted by newer single-tablet regimens like Genvoya.
- 5Research and Development (R&D) expenses increased by 6% to $3.0 billion, reflecting continued investment in pipeline development.
- 6The company ended the year with a strong cash position of $26.2 billion.
- 7Gilead initiated a quarterly dividend of $0.43 per share and continued its aggressive share repurchase program.